Completed PHASE1 INTERVENTIONAL 12-arm NCT01951677

Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine

Phase 1 Randomized, Controlled, Double-blind Study to Compare the Safety and Effectiveness of Hepatitis B Vaccines in Individuals With Renal Impairment, Diabetes Mellitus or Age Greater Than 40 Years

Sponsor: Flinders Medical Centre

Conditions Exposure to Hepatitis B Virus

Interventions Advax-1(TM) Advax-2(TM) Advax-3(TM) Alum HBsAg PreS HBsAg

Updated 6 times since 2017 Last updated: May 6, 2019 Started: Jul 31, 2013 Primary completion: Oct 31, 2017 Completion: May 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Exposure to Hepatitis B Virus and is currently completed. Flinders Medical Centre leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Jun 2019 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Flinders Medical Centre
Vaxine Pty Ltd

Data source: Vaxine Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia